New drug combo targets stubborn lymphoma after CAR-T failure
NCT ID NCT06760156
First seen Jan 11, 2026 · Last updated Jun 17, 2026 · Updated 18 times
Summary
This study tests a combination of two drugs, tafasitamab and lenalidomide, in people with large B-cell lymphoma that still shows signs of disease after CAR-T cell therapy. The goal is to see if this drug pair can shrink or eliminate the remaining cancer. About 28 adults will take part for roughly 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.